• Filing Date: 2019-08-13
  • Form Type: 10-Q
  • Description: Quarterly report
v3.19.2
Research Collaboration and Sub-licensing Agreements (Details)
€ in Thousands
3 Months Ended 6 Months Ended
May 07, 2019
antibody_and_vaccine
protein
May 05, 2019
Jun. 30, 2017
USD ($)
Jun. 30, 2017
EUR (€)
Jun. 30, 2019
USD ($)
collaboration_project
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
collaboration_project
Jun. 30, 2018
USD ($)
Apr. 26, 2019
Dec. 31, 2018
USD ($)
Jun. 30, 2017
EUR (€)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Duration of agreement     2 years 2 years              
Payment for research and development agreement     $ 1,100,000 € 1,000              
Prepaid research and development | $         $ 100,000   $ 100,000     $ 300,000  
Research and development - related party | $         $ 336,310 $ 340,849 $ 725,783 $ 733,398      
Collaborative Arrangement | Serum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of antibodies and vaccines for development and commercialization | antibody_and_vaccine 12                    
Option to obtain exclusive commercial sub-license for number of proteins | protein 12                    
Research funding, milestone payments and royalties, period 15 years                    
Novovet                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Equity percentage                 20.00%    
Alphazyme                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Equity percentage   7.50%                  
Ownership interest consideration receivable upon extension of exclusivity period   2.50%                  
Alphazyme | Collaborative Arrangement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Exclusivity period   18 months                  
Option to extend exclusivity period   12 months                  
RSA                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Payment for research and development agreement | €       € 1,000              
Payment for additional development and commercialization | €                     € 1,500
RSA | Minimum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue sharing, percentage     50.00% 50.00%              
RSA | Maximum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue sharing, percentage     75.00% 75.00%              
RSA | BDI Holdings                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Equity interest acquired     16.10% 16.10%              
RSA | VLPbio                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Equity interest acquired     3.30% 3.30%              
RSA | BDI                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Duration of agreement     2 years 2 years              
Obligation for payment for research and development, minimum | €                     936
Obligation for payment for research and development, maximum | €                     € 8,000
RSA | BDI | Minimum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue sharing, percentage     50.00% 50.00%              
RSA | BDI | Maximum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue sharing, percentage     75.00% 75.00%              
SFA                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Duration of agreement     2 years 2 years              
Obligation for payment for research and development, minimum | $     $ 1,000,000                
Outstanding commitment | $     $ 1,000,000                
Number of collaboration project, completed | collaboration_project         4   4        
Number of collaboration project, in progress | collaboration_project         3   3